Cancer Molecular Diagnostics
| Full details for "RQ BCR::ABL1 p210". | |
|---|---|
Name |
RQ BCR::ABL1 p210 |
Alternative name/Profile |
MRD testing for BCR::ABL1 (p210) in Chronic Myeloid Leukaemia |
Department |
Cancer Molecular Diagnostics |
Investigation |
Monitoring of measurable residual disease (MRD) in Chromic Myeloid Leukaemia |
Specimen type |
Bone Marrow |
Sample type |
|
Sample container & volume |
>3ml in RPMI medium |
Frequency of analysis |
Weekly |
Turnaround time |
10-15 working days |
Availability |
Monday - Friday 9.30am to 5.00pm |
Notes |
For real-time quantitative PCR (RQ-PCR) of BCR::ABL1 in patients receiving tyrosine kinase inhibitor therapy, peripheral blood samples are preferable. Samples for molecular testing should arrive in the laboratory as soon as possible post collection. Samples should be refrigerated at 4°C until dispatch. |
Related links |
|
Reference range |
|
Last updated |
Tue, 17 Feb 2026 07:59:27 GMT |